Modus Therapeutics: Clinical development pro

Modus Therapeutics AB, a Karolinska Development portfolio company developing treatments for sickle cell disease, has appointed Ellen K. Donnelly as CEO. Donnelly joins from Pfizer, Inc, where she most recently was responsible for Clinical Operations for the Neuroscience and Pain therapeutic area.

Read more

EuropaBio: Regulatory experience

The European biotech industry association EuropaBio has named John Brennan as its new Secretary General. The life sciences expert will take over his new position in June. 
Read more

Bioiberica: A boost to the company

In April, Luis Solera assumes the position of CEO at Barcelona-based biotech Bioiberica. He joins from LIPSA, a leading family business in the oils and fats sector.

Read more

Karolinska Development: Changes at the top

Following the resignation of erstwhile CEO Jim Van heusden, Karolinska Development has promoted Viktor Drvota to the position of head of the company. Drvota held the position of Chief Investment Officer before.
Read more

e-Therapeutics: Newly in charge

AIM-listed drug discovery company e-Therapeutics plc has a new head. In early April, Raymond Barlow took over as Chief Executive Officer. 
Read more

Domainex: Navigating the growth

Domainex has a new Executive Chairman: Timo Veromaa has been appointed to the Board of the British drug discovery services company.
Read more

Hansa Medical: Taking charge of medical affairs

Hansa Medical, Lund-based developer of novel immunomodulatory enzymes, has recruited Sam Agus as Chief Medical Officer. Agus joins from H. Lundbeck AS, where he was Chief Specialist, Medical Affairs Neurology. 
Read more

Crescendo Biologics: Aid for late-stage development

Cambridge-based immuno-oncology developer Crescendo Biologics had named Philip Bland-Ward as its Chief Scientific Officer. He joins Crescendo from Kymab where he was responsible for leading its most advanced development programme.
Read more

EFPIA: Engaging for pharma innovation

In April, Nathalie Moll has taken on her new job as Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA). Moll is also Secretary General of Europe’s largest biotech industry group EuropaBio. 

Read more

Endomag: Going beyond the horizons

Cancer healthcare company Endomag, founded in 2007 as a spin-out from the University College London (UCL) and the University of Houston, has appointed Peter Keen as non-executive director. Keen will focus on supporting the company as it further extends its international reach.
Read more